

Influence of polyvascular disease on cardiovascular event Registry

Vascular Medicine

15, 259-265

DOI: [10.1177/1358863x10373299](https://doi.org/10.1177/1358863x10373299)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Increased lipoprotein(a) is associated with polyvascular disease in patients undergoing coronary artery bypass graft. <i>Atherosclerosis</i> , 2011, 219, 285-290.	0.4	9
3	The Possible Risk of Cancer in Claudicants. <i>Angiology</i> , 2011, 62, 579-584.	0.8	9
4	Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study. <i>Clinical Interventions in Aging</i> , 2012, 7, 27.	1.3	12
5	Correlation between serum C1q-adiponectin/total adiponectin ratio and polyvascular lesions detected by vascular ultrasonography in Japanese type 2 diabetics. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 376-385.	1.5	17
6	Prevalence and Clinical Outcome of Polyvascular Atherosclerotic Disease in Patients Undergoing Coronary Intervention. <i>Circulation Journal</i> , 2013, 77, 89-95.	0.7	47
7	Cardiovascular Events in Patients with Atherothrombotic Disease: A Population-Based Longitudinal Study in Taiwan. <i>PLoS ONE</i> , 2014, 9, e92577.	1.1	19
8	The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients. <i>European Journal of Clinical Investigation</i> , 2014, 44, 231-239.	1.7	11
9	Contemporary outcomes with percutaneous vascular interventions for peripheral critical limb ischemia in those with and without poly-vascular disease. <i>Vascular Medicine</i> , 2014, 19, 491-499.	0.8	33
10	Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 190-201.	1.0	7
11	C-reactive protein, renal function, and cardiovascular outcome in patients with symptomatic peripheral artery disease and preserved left ventricular systolic function. <i>Croatian Medical Journal</i> , 2015, 56, 351-356.	0.2	23
12	DIABETES AND CRITICAL LIMB ISCHEMIA: THE DEADLY DUO IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE. <i>Acta Clinica Croatica</i> , 2016, 55, 240-245.	0.1	7
13	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 609-622.	6.1	24
14	Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017, 119, 1146-1152.	0.7	28
15	Peripheral Vascular Interventions and the Cardiologist: More Than a Pain in the Neck, a Belly Ache, an Arm and a Leg. <i>Canadian Journal of Cardiology</i> , 2017, 33, 708-710.	0.8	0
16	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	1.2	6
17	Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. <i>International Journal of Cardiology</i> , 2018, 261, 6-11.	0.8	12
18	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	1.0	171
19	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22

#	ARTICLE	IF	CITATIONS
20	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
21	Cardiovascular Risk Evaluation in Patients with Critical Leg Ischemia before Vascular Surgery. , 2018, ,		0
22	Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. <i>JAMA Network Open</i> , 2018, 1, e185239.	2.8	68
23	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	5.5	96
24	Serum total bilirubin concentration in patients with type 2 diabetes as a possible biomarker of polyvascular disease. <i>Diabetology International</i> , 2018, 9, 129-135.	0.7	6
25	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154
26	How the Cow Ate the CABG. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1187-1189.	1.2	0
27	Antithrombotic Agents. <i>Circulation Research</i> , 2019, 124, 426-436.	2.0	76
29	Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. <i>American Heart Journal</i> , 2019, 213, 47-56.	1.2	8
30	Unmet medical needs in intermittent Claudication with diabetes and coronary artery disease—A real-world analysis on 21% 197 PAD patients. <i>Clinical Cardiology</i> , 2019, 42, 629-636.	0.7	10
31	Primary and Novel Lipid-Lowering Therapies to Reduce Risk in Patients With Peripheral Arterial Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 94.	0.4	1
32	Myocardial infarction and peripheral arterial disease: Treatment patterns and long-term outcome in men and women results from a Swedish nationwide study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1426-1434.	0.8	16
33	The myth of “stable” coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	6.1	89
34	A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease. <i>Angiology</i> , 2020, 71, 303-314.	0.8	13
35	Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 251-264.	1.2	47
36	Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. <i>Atherosclerosis</i> , 2020, 315, 10-17.	0.4	17
37	Impact of peripheral artery disease on prognosis after myocardial infarction: The J-MINUET study. <i>Journal of Cardiology</i> , 2020, 76, 402-406.	0.8	3
38	Added value of femoral artery atherosclerosis for determining severity of white matter lesion by carotid atherosclerosis: a magnetic resonance imaging study. <i>Acta Radiologica</i> , 2021, 62, 1112-1121.	0.5	1

#	ARTICLE	IF	CITATIONS
39	Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease. American Journal of Cardiology, 2020, 128, 28-34.	0.7	3
40	Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. American Journal of Preventive Cardiology, 2020, 1, 100010.	1.3	17
41	Development of a 3-Dimensional Prognostic Score for Patients With Symptomatic Peripheral Artery Disease: PAD ^{3D} Score. Angiology, 2020, 71, 658-665.	0.8	2
42	Coronary Artery Disease in the Arab World. , 2021, , 1-16.		0
43	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. Journal of Clinical Medicine, 2021, 10, 886.	1.0	5
44	Successful Peripheral Vascular Intervention in Patients with High-risk Comorbidities or Lesion Characteristics. Current Cardiology Reports, 2021, 23, 32.	1.3	0
45	Association of Polyvascular Disease and Elevated Interleukin-6 With Outcomes in Acute Ischemic Stroke or Transient Ischemic Attack. Frontiers in Neurology, 2021, 12, 661779.	1.1	3
46	Impact of Multivascular Disease on Cardiovascular Mortality and Morbidity in Patients Receiving Hemodialysis: Ten-Year Outcomes of the Q-Cohort Study. Journal of Atherosclerosis and Thrombosis, 2021, 28, 385-395.	0.9	3
47	Coronary Artery Disease in the Arab World. , 2021, , 2855-2870.		1
48	Polyvascular Disease: Definition, Epidemiology, Relevance. , 2015, , 4779-4810.		6
49	Diabetes, renal dysfunction, inflammation, and anemia: the deadly quartet in peripheral artery disease. Endocrine Oncology and Metabolism, 2016, 2, 82-87.	0.0	3
50	Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. Drugs in Context, 2020, 9, 1-15.	1.0	3
51	PREVALENCE OF MULTI-FOCAL ATHEROSCLEROTIC PATHOLOGY ACROSS AGE GROUPS. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 63-69.	0.4	0
52	Polyvascular Disease: Definition, Epidemiology, and Relevance. , 2014, , 1-37.		3
53	Arterial calcium scoring â€“ a â€œdisease-screeningâ€ approach?. Vasa - European Journal of Vascular Medicine, 2018, 47, 341-343.	0.6	0
54	Polyvascular disease in patients with myocardial infarction and chronic kidney disease. Terapevticheskii Arkhiv, 2019, 91, 73-79.	0.2	2
55	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCCEL trial. Atherosclerosis, 2021, 338, 1-6.	0.4	6
56	Cardiovascular morbidities in postoperative colorectal cancer patients. Scientific Reports, 2021, 11, 21359.	1.6	2

#	ARTICLE	IF	CITATIONS
57	The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 1923-30.	1.3	4
58	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> . 2022, 20, 1193-1205.	1.9	3
59	Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1223-1235.	1.2	8
60	Long-Term Outcome in Patients With Acute Ischemic Stroke and Heart Failure. <i>Circulation Journal</i> , 2023, 87, 401-408.	0.7	4
61	Presence of asymptomatic Peripheral Arterial Disease in combination with common risk factors elevates the cardiovascular risk Substantially. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2022, 13, 200130.	0.4	4
62	Polyvascular Disease in the Gulf Region: Concealed Marker of Poor Outcomes in Acute Coronary Syndrome. <i>Current Problems in Cardiology</i> , 2022, , 101357.	1.1	0
63	Patients with Polyvascular Disease: A Very High-risk Group. <i>Current Vascular Pharmacology</i> , 2022, 20, 475-490.	0.8	1
64	Dietary Risk Factors and Eating Behaviors in Peripheral Arterial Disease (PAD). <i>International Journal of Molecular Sciences</i> , 2022, 23, 10814.	1.8	10
65	Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial. <i>Current Atherosclerosis Reports</i> , 2023, 25, 85-93.	2.0	1